Reports Q3 revenue $244,361, consensus $280k. “The past quarter was a watershed period for Femasys, gaining FDA clearance to market one of our two lead programs, FemaSeed, via a 510(k) pre-market submission allowing for the accelerated commercialization of this important and innovative infertility treatment,” said Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys. “Also, we have been rapidly initiating academic sites for participation in the landmark, pivotal FINALE trial of our leading, late-clinical stage product candidate, FemBloc, bringing us closer to making this much needed non-surgical permanent birth control alternative available to women.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FEMY:
- Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
- Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
- Femasys completes EU MDR final audit
- Femasys Inc. EU MDR Final Audit Successfully Completed
- Femasys to showcase FemBloc, other products at AAGL meeting
